These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22465275)

  • 1. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease.
    Eren F; Kurt R; Ermis F; Atug O; Imeryuz N; Yilmaz Y
    Clin Biochem; 2012 Jun; 45(9):655-8. PubMed ID: 22465275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology.
    Colak Y; Senates E; Ozturk O; Yilmaz Y; Zemheri E; Yilmaz Enc F; Ulasoglu C; Aksaray S; Bozbeyoglu SG; Kiziltas S; Kurdas OO; Tuncer I
    Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):255-61. PubMed ID: 22157234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration.
    Yilmaz Y; Kurt R; Eren F; Imeryuz N
    Scand J Clin Lab Invest; 2011 Dec; 71(8):631-6. PubMed ID: 21859358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.
    Schreuder TC; Marsman HA; Lenicek M; van Werven JR; Nederveen AJ; Jansen PL; Schaap FG
    Am J Physiol Gastrointest Liver Physiol; 2010 Mar; 298(3):G440-5. PubMed ID: 20093562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum galectin-3 levels in patients with nonalcoholic fatty liver disease.
    Yilmaz Y; Eren F; Kurt R; Yonal O; Polat Z; Senates E; Bacha M; Imeryuz N
    Clin Biochem; 2011 Aug; 44(12):955-8. PubMed ID: 21635880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease.
    Aktas B; Yilmaz Y; Eren F; Yonal O; Kurt R; Alahdab YO; Celikel CA; Ozdogan O; Imeryuz N; Kalayci C; Avsar E
    Metabolism; 2011 Apr; 60(4):544-9. PubMed ID: 20580037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis.
    Yilmaz Y; Eren F; Ayyildiz T; Colak Y; Kurt R; Senates E; Tuncer I; Dolar E; Imeryuz N
    Clin Chim Acta; 2011 Nov; 412(23-24):2296-9. PubMed ID: 21888902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease.
    Targher G; Bertolini L; Scala L; Cigolini M; Zenari L; Falezza G; Arcaro G
    Nutr Metab Cardiovasc Dis; 2007 Sep; 17(7):517-24. PubMed ID: 16928437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease.
    Targher G; Bertolini L; Rodella S; Zoppini G; Scala L; Zenari L; Falezza G
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):679-83. PubMed ID: 16712671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease.
    Senates E; Yilmaz Y; Colak Y; Ozturk O; Altunoz ME; Kurt R; Ozkara S; Aksaray S; Tuncer I; Ovunc AO
    Metab Syndr Relat Disord; 2011 Aug; 9(4):287-90. PubMed ID: 21417913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.
    Li H; Fang Q; Gao F; Fan J; Zhou J; Wang X; Zhang H; Pan X; Bao Y; Xiang K; Xu A; Jia W
    J Hepatol; 2010 Nov; 53(5):934-40. PubMed ID: 20675007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.
    Wieckowska A; Zein NN; Yerian LM; Lopez AR; McCullough AJ; Feldstein AE
    Hepatology; 2006 Jul; 44(1):27-33. PubMed ID: 16799979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease.
    Nobili V; Alkhouri N; Alisi A; Ottino S; Lopez R; Manco M; Feldstein AE
    Clin Gastroenterol Hepatol; 2009 May; 7(5):575-9. PubMed ID: 19268270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of serum ceruloplasmin associate with pediatric nonalcoholic fatty liver disease.
    Nobili V; Siotto M; Bedogni G; Ravà L; Pietrobattista A; Panera N; Alisi A; Squitti R
    J Pediatr Gastroenterol Nutr; 2013 Apr; 56(4):370-5. PubMed ID: 23154483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease.
    Yilmaz Y; Eren F; Colak Y; Senates E; Celikel CA; Imeryuz N
    Scand J Gastroenterol; 2012 Dec; 47(12):1488-93. PubMed ID: 23137022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
    Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
    Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
    Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
    J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease.
    Targher G; Bertolini L; Rodella S; Zoppini G; Zenari L; Falezza G
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):337-41. PubMed ID: 16487446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD).
    Madan K; Bhardwaj P; Thareja S; Gupta SD; Saraya A
    J Clin Gastroenterol; 2006; 40(10):930-5. PubMed ID: 17063114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents.
    Wojcik M; Janus D; Dolezal-Oltarzewska K; Kalicka-Kasperczyk A; Poplawska K; Drozdz D; Sztefko K; Starzyk JB
    J Pediatr Endocrinol Metab; 2012; 25(11-12):1089-93. PubMed ID: 23329754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.